Lördag 13 September | 21:25:52 Europe / Stockholm

Prenumeration

2025-08-27 14:33:00

BioInvent has announced a reshaping of its pipeline, concentrating on its two most advanced clinical programs and pausing two early-stage projects. Although the market initially reacted cautiously, the company emphasizes that the move is designed to accelerate value creation and sharpen its focus. We reached out to CEO Martin Welschof to learn more.

Read the full interview at biostock.se:

BioInvent comments on its strategic portfolio shift

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/